Improvement of Midpoint Imputation for Estimation of Median Survival Time for Interval-Censored Time-to-Event Data
Therapeutic Innovation & Regulatory Science · 2024
DOI: 10.1007/s43441-024-00640-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Innovation & Regulatory Science, 2024. Verfasst von Yuki Nakagawa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Biometrics Department, Chugai Pharmaceutical Co., Ltd., 2-1-1 Nihonbashi-Muromachi, Chuo-Ku, Tokyo, 103-8324, Japan. nakagawa.yuki99@chugai-pharm.co.…. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Progression-free survival (PFS) is used to evaluate treatment effects in cancer clinical trials. Disease progression (DP) in patients is typically determined by radiological testing at several scheduled tumor-assessment time points. This produces a discrepancy between the true progression time and the observed progression time. When the observed progression time is considered as the true progression time, a positively biased PFS is obtained for some patients, and the estimated survival function derived by the Kaplan-Meier method is also biased. METHODS: While the midpoint imputation method is available and replaces interval-censored data with midpoint data, it unrealistically assumes that several DPs occur at the same time point when several DPs are observed within the same tumor-assessment interval. We enhanced the midpoint imputation method by replacing interval-censored data with equally spaced timepoint data based on the number of observed interval-censored data within the same tumor-assessment interval. RESULTS: The root mean square error of the median of the enhanced method is almost always smaller than that of the midpoint imputation regardless of the tumor-assessment frequency. The coverage probability of the enhanced method is close to the nominal confidence level of 95% in most scenarios. CONCLUSION: We believe that the enhanced method, which builds upon the midpoint imputation method, is more effective than the midpoint imputation method itself.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Biometrics Department, Chugai Pharmaceutical Co., Ltd., 2-1-1 Nihonbashi-Muromachi, Chuo-Ku, Tokyo, 103-8324, Japan. nakagawa.yuki99@chugai-pharm.co.jp.
- Department of Management Science, Graduate School of Engineering, Tokyo University of Science, Tokyo, Japan. nakagawa.yuki99@chugai-pharm.co.jp.
- Department of Information and Computer Technology, Faculty of Engineering, Tokyo University of Science, Tokyo, Japan.
ORCID-Profile: Yuki Nakagawa
Zitieren
APA
Nakagawa, Y., & Sozu, T. (2024). Improvement of Midpoint Imputation for Estimation of Median Survival Time for Interval-Censored Time-to-Event Data. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-024-00640-7
Vancouver
Nakagawa Y, Sozu T. Improvement of Midpoint Imputation for Estimation of Median Survival Time for Interval-Censored Time-to-Event Data. Therapeutic Innovation & Regulatory Science. 2024. doi:10.1007/s43441-024-00640-7
BibTeX
@article{Nakagawa2024,
author = {Nakagawa, Yuki and Sozu, Takashi},
title = {Improvement of Midpoint Imputation for Estimation of Median Survival Time for Interval-Censored Time-to-Event Data},
journal = {Therapeutic Innovation & Regulatory Science},
year = {2024},
doi = {10.1007/s43441-024-00640-7}
}
EUVIMED